Stephen Freedland, MD

Articles by Stephen Freedland, MD

Final EMBARK Data Show “Almost Unprecedented” Reduction in Risk of Death With Enzalutamide Plus ADT in Biochemically Recurrent Prostate Cancer

October 19th 2025

Stephen Freedland, MD, highlighted data showing significant overall survival benefits in the EMBARK trial and discussed the continued role of monotherapy in preserving quality of life for select patients.

Latest Updated Articles

Trending on Pharmacy Times

In the Fragmented Landscape of Long COVID Care, Pharmacists Are Essential

Therapeutic Cancer Vaccines: Are We There Yet?

Amivantamab Shows 45% Response Rate in Pretreated Head and Neck Cancer: OrigAMI-4 Findings

FDA Approves Gazyva for Active Lupus Nephritis

EV-303 Trial Shows Unprecedented Survival Benefit With Enfortumab Vedotin Plus Pembrolizumab in Cisplatin-Ineligible Bladder Cancer